Aristotle University Of Thessaloniki (AUTH)
Ο ρόλος των μεταλλοπρωτεϊνασών (MMP-1, MMP-2) και των νεότερων βιοχημικών δεικτών του οστικού μεταβολισμού σε ασθενείς με χρόνια νεφρική νόσο
Abstract
dc:descriptionIntroduction: Chronic kidney disease (CKD) is related to abnormal calcium, phosphate, parathyroid hormone (PTH) and vitamin D serum levels that are associated with impaired bone metabolism leading to a specific type of osteopathy called Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). CKD-MBD occurs when renal function is progressively reduced and includes a series of disturbances in bone modeling and remodeling, leading to bone disease and concomitant fractures. The aim of this study was to assess the levels of the Matrix metalloproteinase-1 and -2 (MMP-1 and MMP -2) in CKD patients of various disease stages in correlation to other bone turnover biochemical markers and to examine the possible role of MMPs in the evaluation of bone disease in uremic patients. Subjects and methods: In this study 60 patients at different stages of pre-dialysis CKD, 20 patients on hemodialysis (HD) and 20 age-matched healthy controls were enrolled. The patients were divided into four groups according to the severity of renal disease and Creatinine Clearance (ClCr). Each group included 20 subjects. The first group was CKD1 (stage 2, ClCr 90-60 ml/min), the second group was CKD2 (stage 3, ClCr 60-30 ml/min), the third group was CKD3 (stage 4, ClCr 30-15 ml/min) and the fourth group was CKD4-ΗD (stage 5, ClCr <15 ml/min). Serum levels of urea, creatinine, calcium, phosphorus, and alkaline phosphatase were estimated by colorimetry. Serum intact parathyroid hormone (i-PTH), osteocalcin (OC), N-terminal propeptide of type I collagen (PINP), and beta-C-terminal telopeptide of type I collagen (β-CTX), were measured by electrochemiluminescence on automatic analyzers. Serum MMP-1 and MMP-2 levels were estimated using a commercial enzyme-linked immunosorbent assay (ELISA). ClCr was calculated using the traditional clearance formula based on a 24-hour urine collection. Results: Significant differences (p<0.0001 & p<0.05) were noted for i-PTH, OC, PINP and β-CTX levels among patients with different stages of CKD and compared to controls. As ClCr is reduced, a gradual increase of the new bone indicators is observed resulting significant differences between the groups (p <0.0001). Levels of i-PTH, OC, PINP and β-CTX were significantly higher (p<0.0001) in dialysis patients. MMP-1 serum levels showed a weak gradual increase with the deterioration of kidney function in CKD patients and had the highest values in hemodialysis patients, which differed significantly from the healthy controls (p<0.05). On the contrary, MMP-2 serum levels showed statistically significant lower levels (p<0.05) among the groups studied and the hemodialysis patients. Positive correlations between i-PTH levels and the other bone markers (OC, PINP and β-CTX) were established while significant positive correlations were also observed among all the bone disease markers tested. It should be also emphasized that all the biochemical bone markers analyzed were significantly negatively correlated with ClCr. MMP-1 showed a significant positive correlation with OC and β- CTX whereas a significant negative correlation was found between MMP-2 and OC. Conclusions: Based on this study we drew to the following conclusions: 1. As the renal disease progresses, the serum levels of i-PTH increase. Increased i-PTH levels demonstrate a high bone turnover as a result of the development of secondary hyperparathyroidism. 2. Bone biochemical markers increase in CKD patients along with the decrease in renal function and even more in hemodialysis patients. Measurement of serum levels of β-CTX, PINP and OC in patients with CKD is useful and shows that these biomarkers of bone metabolism are clinically significant for the evaluation and follow-up of renal bone disease. 3. Concerning MMP-1, an upward trend of MMP-1 with the stage of the disease was observed. MMP-1 serum levels correlated positively with OC and β- CTX. These significant correlations between bone markers and MMP-1 suggest an association between bone turnover and MMP-1 serum levels. MMP-1 seems to interfere actively in bone turnover and could possibly be involved in the process of bone disease.4. MMP-2 levels did not show significant changes among the groups, excluding dialysis patients where, contrary to what was expected, MMP-2 showed a marked decrease. MMP-2 serum levels were found significantly decreased in hemodialysis patients and showed a negative correlation with OC. In the present study increased levels of bone markers in patients with CKD underline their predictive value and their importance in the assessment and follow up of renal bone disease. MMPs serum levels may reflect bone remodeling rate in these patients, since they seem to correlate with the bone markers. Further studies are needed to elucidate the pathophysiological mechanisms reflected by these observations.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Thysiadou, Aikaterini
- Θυσιάδου, Αικατερίνη
Subjects
dc:subject × 14- Μεταλλοπρωτεϊνάση-1
- Μεταλλοπρωτεϊνάση-2
- Βιοχημικοί οστικοί δείκτες
- Διαταραχή οστών και μετάλλων
- Χρόνια νεφρική νόσος
- Matrix metalloproteinase-1
- Matrix metalloproteinase-2
- Biochemical markers of bone metabolism
- Mineral bone disease
- Chronic kidney disease
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43600